ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Series 1 Shares - 70million Consolidable or not

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon Jul 01, 2022 2:02pm

2133 Views

Post# 34796492

RE:RE:RE:RE:RE:RE:RE:RE:RE:Series 1 Shares - 70million Consolidable or not

So who are investors? Are they people that put in their money to finance directly into the company coffers or people who buy shares from other people ...I fall into the second category...I have never contributed to the company directly...so am I an investor and being in this category , how are the Boston group going to push me out of opportunity of making money when they want the stock to go up as high as possible.

<< Previous

Bullboard Posts

Next >>

Gold, growth and sustainability in focus for Mandalay Resources